Financial

New Consumer Health Company would be a Global Leader with Iconic Brands and Products that Touch Over One Billion Lives Every Day Johnson & Johnson would Remain a Global Leader in Healthcare, Focused on Major Unmet Medical Needs and Materially Advancing Standard of Care through Biopharmaceutical and Medical Device Innovation and Technology Separation Designed to Enhance Operational Performance and Strategic Flexibility, Benefiting Patients and Consumers and Unlocking Value for All Stakeholders New Consumer Health Company Expected to Complete Separation in 18 to 24 Months Johnson & Johnson to Host Investor Conference Call Today at 8:30 a.m. ET

Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%* Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%* Company increasing 2021 Full-Year Guidance

Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANTTM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer